Study of Lorlatinib in ROS1 Rearranged NSCLC

NCT03612154 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG: Lorlatinib

Sponsor

National Cancer Center, Korea